Literature DB >> 27580097

Current and potential therapeutic targets of glucagon-like peptide-2.

Kaori Austin1, Melanie A Markovic1, Patricia L Brubaker2.   

Abstract

Glucagon-like peptide-2 (GLP-2) is a gut hormone that promotes highly specific growth and function of the intestinal epithelium. Recent studies have begun to elucidate the complex mechanism of action of GLP-2, which is mediated indirectly through other intestinal factors. Although a long-acting GLP-2 analog has recently been approved for treatment of adult patients with short bowel syndrome, there remain numerous conditions characterized by intestinal insufficiency for which pre-clinical studies, as well as some limited clinical data, support further consideration of GLP-2 for expanded therapeutic use.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27580097     DOI: 10.1016/j.coph.2016.08.008

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  7 in total

1.  Increased GLP2R expression in gastric chief cells of patients with severe obesity regardless of diabetes status.

Authors:  F Li; L Lu; Y Peng; Y Zhang; J Gao; D Zhou; D Zhou; H Sheng; S Qu
Journal:  Int J Obes (Lond)       Date:  2017-03-24       Impact factor: 5.095

2.  Glucagon-Like Peptide-2 Improve Intestinal Mucosal Barrier Function in Aged Rats.

Authors:  W Ren; J Wu; L Li; Y Lu; Y Shao; Y Qi; B Xu; Y He; Y Hu
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

Review 3.  Therapeutic Potential of GLP-2 Analogs in Gastrointestinal Disorders: Current Knowledge, Nutritional Aspects, and Future Perspectives.

Authors:  Dimitris Kounatidis; Natalia G Vallianou; Dimitrios Tsilingiris; Gerasimos Socrates Christodoulatos; Eleni Geladari; Theodora Stratigou; Irene Karampela; Maria Dalamaga
Journal:  Curr Nutr Rep       Date:  2022-08-06

4.  Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes.

Authors:  Shan Lang; Jin Yang; Kun Yang; Liangbiao Gu; Xiaona Cui; Tianjiao Wei; Junling Liu; Yunyi Le; Haining Wang; Rui Wei; Tianpei Hong
Journal:  BMJ Open Diabetes Res Care       Date:  2020-03

5.  A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor.

Authors:  Wen Sun; Li-Nan Chen; Qingtong Zhou; Li-Hua Zhao; Dehua Yang; Huibing Zhang; Zhaotong Cong; Dan-Dan Shen; Fenghui Zhao; Fulai Zhou; Xiaoqing Cai; Yan Chen; Yan Zhou; Sarina Gadgaard; Wijnand J C van der Velden; Suwen Zhao; Yi Jiang; Mette M Rosenkilde; H Eric Xu; Yan Zhang; Ming-Wei Wang
Journal:  Cell Res       Date:  2020-11-25       Impact factor: 25.617

6.  GLP-2 Prevents Neuronal and Glial Changes in the Distal Colon of Mice Chronically Treated with Cisplatin.

Authors:  Patrizia Nardini; Alessandro Pini; Anne Bessard; Emilie Duchalais; Elena Niccolai; Michel Neunlist; Maria Giuliana Vannucchi
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

7.  Variation in the Evolution and Sequences of Proglucagon and the Receptors for Proglucagon-Derived Peptides in Mammals.

Authors:  David M Irwin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-12       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.